GALT
Price
$4.99
Change
-$0.06 (-1.19%)
Updated
Oct 17 closing price
Capitalization
319.66M
29 days until earnings call
RNAC
Price
$9.01
Change
-$0.41 (-4.35%)
Updated
Oct 17 closing price
Capitalization
234.28M
Interact to see
Advertisement

GALT vs RNAC

Header iconGALT vs RNAC Comparison
Open Charts GALT vs RNACBanner chart's image
Galectin Therapeutics
Price$4.99
Change-$0.06 (-1.19%)
Volume$177.9K
Capitalization319.66M
Cartesian Therapeutics
Price$9.01
Change-$0.41 (-4.35%)
Volume$114.7K
Capitalization234.28M
GALT vs RNAC Comparison Chart in %
GALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GALT vs. RNAC commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GALT is a Hold and RNAC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (GALT: $4.99 vs. RNAC: $9.01)
Brand notoriety: GALT and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GALT: 61% vs. RNAC: 165%
Market capitalization -- GALT: $319.66M vs. RNAC: $234.28M
GALT [@Biotechnology] is valued at $319.66M. RNAC’s [@Biotechnology] market capitalization is $234.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GALT’s FA Score shows that 0 FA rating(s) are green whileRNAC’s FA Score has 0 green FA rating(s).

  • GALT’s FA Score: 0 green, 5 red.
  • RNAC’s FA Score: 0 green, 5 red.
According to our system of comparison, GALT is a better buy in the long-term than RNAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GALT’s TA Score shows that 4 TA indicator(s) are bullish while RNAC’s TA Score has 4 bullish TA indicator(s).

  • GALT’s TA Score: 4 bullish, 4 bearish.
  • RNAC’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both GALT and RNAC are a good buy in the short-term.

Price Growth

GALT (@Biotechnology) experienced а +5.72% price change this week, while RNAC (@Biotechnology) price change was -3.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

GALT is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GALT($320M) has a higher market cap than RNAC($234M). GALT YTD gains are higher at: 286.822 vs. RNAC (-49.693). GALT has higher annual earnings (EBITDA): -33.52M vs. RNAC (-118.73M). RNAC has more cash in the bank: 160M vs. GALT (13.8M). RNAC has less debt than GALT: RNAC (13.3M) vs GALT (121M). RNAC has higher revenues than GALT: RNAC (1.03M) vs GALT (0).
GALTRNACGALT / RNAC
Capitalization320M234M137%
EBITDA-33.52M-118.73M28%
Gain YTD286.822-49.693-577%
P/E RatioN/A1.98-
Revenue01.03M-
Total Cash13.8M160M9%
Total Debt121M13.3M910%
FUNDAMENTALS RATINGS
GALT vs RNAC: Fundamental Ratings
GALT
RNAC
OUTLOOK RATING
1..100
955
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
63100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3685
P/E GROWTH RATING
1..100
10040
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GALT's Valuation (94) in the Biotechnology industry is in the same range as RNAC (99). This means that GALT’s stock grew similarly to RNAC’s over the last 12 months.

GALT's Profit vs Risk Rating (63) in the Biotechnology industry is somewhat better than the same rating for RNAC (100). This means that GALT’s stock grew somewhat faster than RNAC’s over the last 12 months.

GALT's SMR Rating (100) in the Biotechnology industry is in the same range as RNAC (100). This means that GALT’s stock grew similarly to RNAC’s over the last 12 months.

GALT's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for RNAC (85). This means that GALT’s stock grew somewhat faster than RNAC’s over the last 12 months.

RNAC's P/E Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for GALT (100). This means that RNAC’s stock grew somewhat faster than GALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GALTRNAC
RSI
ODDS (%)
Bearish Trend 6 days ago
86%
Bullish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
85%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 13 days ago
81%
Bullish Trend 18 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
GALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VCISY35.580.14
+0.40%
Vinci SA
LMPMY3.38N/A
N/A
Lee & Man Paper Manufacturing Ltd.
SKSUY97.95N/A
N/A
Sekisui Chemical Co.
STGAF0.65N/A
N/A
AFENTRA PLC
NUMIF0.04N/A
-4.29%
Numinus Wellness Inc.

GALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, GALT has been loosely correlated with BCAB. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if GALT jumps, then BCAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GALT
1D Price
Change %
GALT100%
-1.19%
BCAB - GALT
36%
Loosely correlated
+12.69%
TAOX - GALT
32%
Poorly correlated
-6.59%
RNAC - GALT
32%
Poorly correlated
-4.35%
ERAS - GALT
27%
Poorly correlated
-4.35%
AVIR - GALT
27%
Poorly correlated
-1.92%
More

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
-4.35%
TAOX - RNAC
91%
Closely correlated
-6.59%
ALLR - RNAC
86%
Closely correlated
-0.35%
NRXP - RNAC
86%
Closely correlated
+4.61%
PALI - RNAC
81%
Closely correlated
+0.58%
OCUL - RNAC
49%
Loosely correlated
-2.95%
More